ArticleBMC bioinformatics2025
LDA-SCGB: inferring lncRNA-disease associations based on condensed gradient boosting.
Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLong non-coding RNAs (lncRNAs) play essential roles in various physiological and pathological processes. Inferring new lncRNA-disease associations (LDAs) not only promotes us to better understand these complex biological processes, but also provides new options for the diagnosis and prevention of diseases.
resultsA novel computational model, LDA-SCGB, is proposed to predict new LDAs. LDA-SCGB first extracts features of each lncRNA-disease pair with singular value decomposition. Next, it classifies unknown lncRNA-disease pairs through the condensed gradient boosting model. The results demonstrated that LDA-SCGB greatly outperformed the other four representative LDA inference methods (SDLDA, LDNFSGB, LDAenDL and LDASR) under 5-fold cross validations on lncRNAs, diseases, and lncRNA-disease pairs on three LDA datasets, which were from lncRNADisease v2.0, MNDR, and lncRNADisease v3.0, respectively. LDA-SCGB was further used to find potential lncRNAs for colorectal cancer, heart failure, and lung adenocarcinoma. The results demonstrated that CCDC26, MIAT, and CCDC26 had higher association probability with colorectal cancer, heart failure, and lung adenocarcinoma, respectively.
conclusionsWe foresee that LDA-SCGB was capable of predicting potential lncRNAs for complex diseases and further assisting in cancer diagnosis and therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.